KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Income from Continuing Operations (2018 - 2025)

Historic Income from Continuing Operations for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to -$32.0 million.

  • Esperion Therapeutics' Income from Continuing Operations fell 289.96% to -$32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$107.8 million, marking a year-over-year decrease of 16011.92%. This contributed to the annual value of -$4.8 million for FY2024, which is 9773.98% up from last year.
  • Esperion Therapeutics' Income from Continuing Operations amounted to -$32.0 million in Q3 2025, which was down 289.96% from -$13.4 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Income from Continuing Operations ranged from a high of $58.2 million in Q1 2024 and a low of -$90.9 million during Q1 2021
  • For the 5-year period, Esperion Therapeutics' Income from Continuing Operations averaged around -$42.9 million, with its median value being -$51.6 million (2023).
  • In the last 5 years, Esperion Therapeutics' Income from Continuing Operations skyrocketed by 19246.41% in 2024 and then plummeted by 17129.71% in 2025.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Income from Continuing Operations stood at -$69.1 million in 2021, then grew by 17.69% to -$56.8 million in 2022, then fell by 1.02% to -$57.4 million in 2023, then surged by 63.71% to -$20.8 million in 2024, then crashed by 53.58% to -$32.0 million in 2025.
  • Its last three reported values are -$32.0 million in Q3 2025, -$13.4 million for Q2 2025, and -$41.5 million during Q1 2025.